We are the only research organization that addresses every phase in the drug discovery process, from initial research all the way to the clinic, in order for new treatments to reach patients.
The Myelin Repair Foundation's Accelerated Research Collaboration™ (ARC™) model addresses every phase in the drug discovery continuum, from initial research all the way to licensing by commercial drug developers. Through the Myelin Repair Foundation’s ongoing management oversight, the ARC model optimizes and integrates the contributions of all those who participate in the value chain of making new medicines.
As a result, the Myelin Repair Foundation’s ARC model:
- Provides an increased number of therapeutically relevant treatment targets in the pipeline
- Translates discoveries made in animal models to the human system
- Builds partnerships with biopharma companies to develop and bring new drugs to market and
- Results in quicker, effective treatments for millions of patients living with chronic diseases, improving their quality of life
The Accelerated Research Collabortation™ (ARC™) Model
Click each section to learn more about the Myelin Repair Foundation's ARC model.
What Others are Saying
“[The Myelin Repair Foundation’s approach] could result in a promising future for big pharma, a sustainable future for the biomedical innovation ecosystem, and most importantly, a healthier future for patients.”
Read about the clinical trial of a potential MS drug to protect and repair myelin.